CN1102097A - Human body early embryo factor and preparation method and its application in pharmaceutics - Google Patents
Human body early embryo factor and preparation method and its application in pharmaceutics Download PDFInfo
- Publication number
- CN1102097A CN1102097A CN93115199A CN93115199A CN1102097A CN 1102097 A CN1102097 A CN 1102097A CN 93115199 A CN93115199 A CN 93115199A CN 93115199 A CN93115199 A CN 93115199A CN 1102097 A CN1102097 A CN 1102097A
- Authority
- CN
- China
- Prior art keywords
- human body
- early embryo
- preparation
- body early
- factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention discloses a human body early embryo factor and its preparation method and application in pharmaceutics. It is obtained by using the following method. The premature embryo tissue of human body is placed in a high-speed pulverizer to make homogenate, and after the homogenate is freezed and taken out, then it is passed through such procedures of centrifugation, filtration, ultrafiltration, sterilizing and blood virus antigen-antibody detection, so that the invention-disclosed premature embryo factor of human body can be obtained, and its molecular weight is twenty thousand, polypeptide is above 1000 mg/ml, ribose body is above 100 mg/ml. It can high-effectively induce Lak cell, activate NK cell, and can be used as anticancer drug, and its raw material is a waste obtained from artificial abortion.
Description
The invention belongs to medical field, relate to people's embryo factor and preparation method thereof, and the anticancer purposes of human body early embryo factor.
Capturing cancer is current bioscience and key subjects medically, in recent decades, the foundation and the development of subjects such as cytology, hereditism, tissue culture, biochemistry, molecular biology, for conquering cancer, the mankind provide new approach---biotherapy, as interferon, transfer factor, interleukin-2, and gene therapy all belongs to this type of.Domestic medical research has the people to extract nerve growth factor from fetal brain at present, also has the people to extract placental transfer factor from Placenta Hominis, and also useful fetal livers splenocyte is made the report of fetal cell suspension, but is not the early stage whole embryo's extraction from the people.Undoubtedly, from people's early stage whole embryo, extract the highly active factor and material, pharmaceutically will be significant.
Purpose of the present invention is exactly to attempt to extract a kind of active factors that the effect of direct inverse cancer inhibitor cell can stimulate, regulate human immunocyte's anti-cancer function again that has from people's body early embryo, produces a kind of new anticancer drugs, is applied to clinical anticancer therapy.
The present invention is achieved in that people's body early embryo tissue is the strongest tissue of human life vigor, adopts following method, can make the human body early embryo factor biological preparation according to modern bioscience principle.
(1) standard-required of raw material collection:
(1) produce the organization material of human body early embryo factor, should be provided by healthy women, be 2-3 months period, and embryonal tissue is live body in vivo, and it is unusual not have morbid state.
(2) take out embryonal tissue after, observe no abnormally, should place preservation below-20 ℃ rapidly.
(3) embryonal tissue is carried out the virus antigen-antibody * detection of blood such as hepatitis B, hepatitis C, feminine gender can be elected formal raw material as.
(2) embryonal tissue that the conformance with standard of collecting is required rinses well with sterile distilled water, puts then in the high speed pulverizer, adds cold distilled water and carries out homogenate, 10000-12000 rev/mins of rotating speeds, 3-5 minutes time, homogenate is put below-20 ℃ freezingly, take out then, melt 35-37 ℃ of water-baths, quick-freezing immediately after the thawing, it is 4.6-4.8 that the homogenate suspension is adjusted pH value, places 1-2 hours down at 4-6 ℃, more than centrifugal then (3000 rev/mins of rotating speeds), take out supernatant.Supernatant is adjusted to PH6.9-7.1, clarification filtration.Clear liquor poured into carry out ultrafiltration in the ultrafilter.The gained ultrafiltrate is the human body early embryo factor preparation.Ultrafiltration gained preparation is carried out degerming, and all kinds of blood disease antigen-antibodies detect, and are distributed into product after all negative.
Adopt said method, extracted human body early embryo factor, and finished the application of human body early embryo factor simultaneously as preparation curing cancers medicine.
Its property of medicine detects and meets the national biological product standards requirement:
1, outward appearance: liquid preparation achromatism and clarity.
2, pH value: 7.0 ± 2
3, molecular weight: 20,000
4, ultra-violet analysis is measured: polypeptide is more than the 1000mg/ml, and ribosome is more than the 100mg/ml.
5, proteins react: 3% sulfosalicylic acid method () property.
6, hot-fluid reaction ().
7, anaphylaxis ().
8, medicine irritation test: subcutaneous injection does not have redness, cirrhosis, necrosis, symptom, the eye conjunctiva splashes into does not have red and swollen, congested phenomenon.
Experiment showed, human body early embryo factor, have following medical application value and purposes:
(1) human body early embryo factor has significant directly inhibitory or killing effect to cancerous cell
Through tissue culture, experiment repeatedly, human body early embryo factor has significant inhibitory or killing effect to human cancer cell (as human cervical carcinoma cell, people hedgehog hydnum cancerous cell etc.), after human cancer cell adds human body early embryo factor, under 35 ℃ of conditions, hatched the cancerous cell disintegrate death more than 90%, and the matched group cancerous cell normal growth under the similarity condition 120 hours.Significant is that human body early embryo factor has no side effect to the human normal cell, adds the human normal cell of human body early embryo factor, (as HFL's diploid cell etc.) the same with matched group, well-grown.
(2) zoopery has tangible tumor-inhibiting action
1. the subcutaneous solid tumor experiment of mice:
Through to 40 mice batch experiments, inject the human body early embryo factor group and compare with matched group, to the inhibitory rate 39.19% of solid tumor, P＜0.001, there were significant differences.
2. mouse ascites cancer experiment:
Warp is to 30 mouse experiments, and every of the average abdominal circumference of mice of injection human body early embryo factor group increases by 0.51 centimetre, P value＞0.050, and average every of matched group increases by 0.98 centimetre, and P value＜0.001, both differ obvious.
3. animal pathology slice probing:
Through the subcutaneous solid tumor pathological section of mice is checked, the cancerous cell of the subcutaneous solid tumor of injection human body early embryo factor is downright bad in a large number, and the matched group cancerous cell does not have downright bad phenomenon, shows that growth has destruction and inhibitory action to human body early embryo factor to animal tumor.
(3) similar interleukin-2 effect is arranged, can efficiently induce the Lak cell to produce the very strong cancer ability of killing
The Lak cell is a kind of specific lymphocyte of separating in the human blood, it under the inducing of interleukin-2 (a kind of B cell growth factor), can become a kind of identity very high, kill carcinous very strong specialized cells, it is fed back to patient, can obtain the antineoplastic therapeutic effect, so interleukin-2 is a kind of cytokine that important clinical medicine using value is arranged.The experiment proved that now human body early embryo factor has the effect of similar interleukin-2, also can efficiently induce the Lak cell, and make it to produce very strong carcinoma killing rate.Detect proof through biochemistry, human body early embryo factor is two kinds of different materials with interleukin-2, does not also contain the latter's material in the former composition.Experimental results show that through 10 times again, human body early embryo factor, inducing on the Lak cellular morphology and quantitatively, with the result that induces of interleukin-2 be similar, and it is also very approaching on carcinoma killing rate, the best carcinoma killing rate of interleukin-2 is 93.2%, and the best carcinoma killing rate of human body early embryo factor is 89.2%, and matched group only is 10.3%.(experimental technique of employing: antibacterial culturing adds MTT microplate reader algoscopy).
(4) can efficiently activate the NK cell, improve the cancerocidal of NK cell
The NK cell is the intravital natural killing cancer cell of mammal, it need not presensitization, also need not participated in by antibody, can dissolution rapidly be arranged to the various tumors of self, can therefore, activate the NK cell be the important symbol that certain biological preparation of check has or not antitumaous effect.Experiment showed, that through 10 human bloods human body early embryo factor activates the NK cell, its activation carcinoma killing rate and interleukin-2 are very approaching.Experimental result: human body early embryo factor group carcinoma killing rate is the 88.2%(meansigma methods), interleukin-2 group carcinoma killing rate is the 91.1%(meansigma methods), and matched group only is 47.2%, shows the human body early embryo factor group apparently higher than matched group, P value＜0.001.
Only inject 8 pin human body early embryo factors through 20 white mice be experiment showed,, can make white mice spleen NK cell kill the active rising 11% of cancer, learn by statistics and handle P＜0.001.
(5) can significantly improve immunologic function
Through getting 40 human blood experiments, human body early embryo factor can make the human leukocyte phagocytic rate rise 88.06% than matched group, and is higher by 23.53% than porcine thymus group; Can make the human leukocyte phagocytic index rise 161.4% than matched group, higher by 72.5% than the plain group of porcine thymus, by α-naphthyl acetate esterase experiment, can make the T lymphocyte activity rise 37.26%, higher by 7% than the plain group of porcine thymus.
Than rising 118.8% with blood leukocytes phagocytic rate before the human body early embryo factor, phagocytic index rises 207.7% after experiment showed, with human body early embryo factor to 15 rat, can make rat T lymphocyte activity rise 117.7%.
From as can be seen above, human body early embryo factor has significant inhibitory or killing effect to cancerous cell, its similar interleukin-2, can efficiently induce the Lak cell, efficiently activate the NK cell, improve the cancerocidal of cell, can significantly improve immunologic function, the human normal cell is had no side effect.The human body early embryo factor raw material is the garbage of artificial abortion, and cost is low, and product price is cheap, and the cost of tiring only is that 1/7-1/10(interleukin-2 domestic price of interleukin-2 is 600,000 yuan of every grams).Manufacture method is simple, and general institute of biological products all can make, and this medicine and preparation method thereof have wide medical applications prospect.
Claims (3)
1, a kind of human body early embryo factor and preparation method thereof and the application in pharmacy is characterized in that the physical-chemical parameter of said human body early embryo factor is: 1. outward appearance: liquid preparation is an achromatism and clarity; 2. pH value: 7.0 ± 2; 3. molecular weight: 20,000; 4. ultra-violet analysis is measured: polypeptide is more than the 1000mg/ml, and ribosome is more than the 100mg/ml; 5. proteins react: 3% sulfosalicylic acid method () property; 6. hot-fluid reaction (); 7. anaphylaxis (); 8. medicine irritation test: subcutaneous injection does not have redness, cirrhosis, downright bad symptom, and the eye conjunctiva splashes into does not have red and swollen, congested phenomenon.
2, according to the described human body early embryo factor of claim 1 and preparation method and the application in pharmacy, it is characterized in that said preparation method is: the standard-required of 1. collecting raw material is: a, produce the organization material of human body early embryo factor, should provide by healthy women, be 2-3 months period, embryonal tissue is live body in vivo, and it is unusual not have morbid state; Should place rapidly below-20 ℃ after b, the taking-up embryonal tissue and preserve; C, virus antigen-antibody * detection, the feminine gender of embryonal tissue being carried out blood such as hepatitis B, hepatitis C can be elected formal raw material as; 2. the embryonal tissue that the conformance with standard of collecting is required rinses well with sterile distilled water, put then in the high speed pulverizer, add cold distilled water and carry out homogenate, 10000-12000 rev/mins of rotating speeds, 3-5 minutes time, homogenate is put below-20 ℃ freezingly, take out then, melt 35-37 ℃ of water-baths, quick-freezing immediately after the thawing, it is 4.6-4.8 that the homogenate suspension is adjusted pH value, places 1-2 hours down at 4-6 ℃, centrifugal then, rotating speed takes out supernatant more than 3000 rev/mins, and supernatant is adjusted to PH6.9-7.1, clarification filtration, clear liquor poured into carry out ultrafiltration in the ultrafilter, the gained ultrafiltrate is the human body early embryo factor preparation, and ultrafiltration gained preparation is carried out degerming, all kinds of blood disease antigen-antibodies detect, and are distributed into product after all negative.
3, according to claim 1,2 described human body early embryo factors and preparation method and the application in pharmacy, it is characterized in that said application in pharmacy is the application of human body early embryo factor as the curing cancers medicine, it is the cancer inhibitting and killing cell directly, induces the Lak cell, activates the NK cell.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN93115199A CN1102097A (en) | 1993-10-29 | 1993-10-29 | Human body early embryo factor and preparation method and its application in pharmaceutics |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN93115199A CN1102097A (en) | 1993-10-29 | 1993-10-29 | Human body early embryo factor and preparation method and its application in pharmaceutics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1102097A true CN1102097A (en) | 1995-05-03 |
Family
ID=4990875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN93115199A Pending CN1102097A (en) | 1993-10-29 | 1993-10-29 | Human body early embryo factor and preparation method and its application in pharmaceutics |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1102097A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1074280C (en) * | 1996-11-26 | 2001-11-07 | 吴成志 | Micro fetus active composite, its preparing process and application in cosmetics |
-
1993
- 1993-10-29 CN CN93115199A patent/CN1102097A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1074280C (en) * | 1996-11-26 | 2001-11-07 | 吴成志 | Micro fetus active composite, its preparing process and application in cosmetics |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2594222B2 (en) | New physiologically active substance-KF | |
| CN104547774A (en) | Traditional Chinese medicine composition for treating liver diseases, and preparation method and applications thereof | |
| CN101724025B (en) | Anti-tumor toad polypeptide and preparation method and application thereof | |
| CN102028700A (en) | Medicinal composition and preparation method thereof | |
| CN112057546A (en) | Propolis ganoderma lucidum spore powder composition and preparation method and application thereof | |
| CN116732125A (en) | Extraction method for improving hypoglycemic activity of mulberry leaf peptide | |
| CA1324084C (en) | Method of extracting a physiological active substance from the husks of pine nuts and anti-contagion medicine made of said extract as principal raw material | |
| JP2746532B2 (en) | Immunity-enhanced foods based on Isaria-type insects | |
| EP0292601A1 (en) | Anti aids drug extracted from lentinus edodes | |
| CN107118283A (en) | Morinda officinalis sugar polymers and its production and use | |
| CN109248177B (en) | Preparation of crocodile amour effective component and application of crocodile amour effective component in oxidation resistance and hepatic fibrosis resistance | |
| CN1102097A (en) | Human body early embryo factor and preparation method and its application in pharmaceutics | |
| KR100373776B1 (en) | A Composition for Cosmetics | |
| EA010735B1 (en) | Medicament normalising reproductive male function and method for preparing thereof | |
| CN1089248C (en) | Medicine for curing diseases in nerve system and its preparing process | |
| Chen et al. | Novel Application of Immunomodulatory Mushroom Polysaccharide (β-Glucan) and Triterpenes for Diabetic Wound Care | |
| CN114712481B (en) | Composite plant source polypeptide and preparation method and application thereof | |
| CA2437690A1 (en) | Ganoderma lucidum spores for treatment of autoimmune diseases | |
| CN1186680A (en) | High effect nontoxic natural anti-cancer agent | |
| CN1965865A (en) | Pharmaceutical application of macrothele raveni toxin | |
| CN117903237A (en) | Process for preparing placenta antigen peptide complex and application thereof | |
| CN1232531C (en) | Production process and use of epidermal cell colyone | |
| CN114903933A (en) | Traditional Chinese medicine for treating eperythrozoonosis of sheep and preparation method and application thereof | |
| CN1156296C (en) | Oral liquid 'Gubao' and its preparing process | |
| CN1120709C (en) | Process for extracting embryo factor of fowls and medicine usage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |